Resverlogix Corp. (TSE:RVX – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.05 and last traded at C$0.06, with a volume of 30297 shares changing hands. The stock had previously closed at C$0.06.
Resverlogix Stock Performance
The firm’s 50 day simple moving average is C$0.06 and its 200-day simple moving average is C$0.06. The company has a market capitalization of C$16.33 million, a price-to-earnings ratio of -1.10 and a beta of 0.78.
Resverlogix (TSE:RVX – Get Free Report) last released its earnings results on Monday, April 1st. The biotechnology company reported C($0.01) earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that Resverlogix Corp. will post -0.22 earnings per share for the current fiscal year.
Resverlogix Company Profile
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Further Reading
- Five stocks we like better than Resverlogix
- 3 Fintech Stocks With Good 2021 Prospects
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- How to Find Undervalued Stocks
- Hilton Demonstrates Asset Light is Right for Investors
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
